What GLP-1 Marketing Reveals About Concierge Medicine's Opportunity

In today's healthcare marketplace, a patient on a compounded GLP-1 medication and a patient enrolled in a concierge medicine practice are now, on average, spending almost exactly the same amount of money each year. That single fact should stop the concierge medicine industry mid-stride, because it says something that no amount of internal debate about our own industry's marketing has managed to say as clearly: patients have already decided they will pay out of pocket for a health outcome. The only open question is which model earns that money, and why.

Today, our team wants to lay out what the numbers actually show, what they suggest about patient and consumer buying behavior, and where the opening sits for concierge medicine's marketing strategy going forward.

GLP-1 telehealth pricing is more fragmented than most patients and physicians realize. A national price index tracking GLP-1 telehealth programs weekly found a cash-pay spread of $149 to $448 a month for the same drug class, depending on provider, dose, and whether the medication is compounded or branded.¹ Once a patient reaches a therapeutic maintenance dose, typically within two to three months, first-year spending for a mid-tier compounded program runs roughly $2,400 to $3,600, and for branded medications purchased through cash-pay channels, $5,400 to $6,600 a year.² Full list price without any insurance or telehealth discount runs from $900 to $1,300 a month.³

Concierge medicine, by comparison, carries a lower and more transparent price tag than most people assume. CMT's own 2026 Industry Pricing Benchmark found the median individual membership fee sitting at $3,200 a year, up from $2,950 in 2025, an 8.4 percent year-over-year increase that outpaced general healthcare inflation. The mean is higher, closer to $4,800, pulled upward by a small number of ultra-premium practices. About 70 percent of concierge practices fall in a $1,800 to $5,500 annual range.⁴²⁰ Direct primary care, concierge medicine's distant membership-medicine cousin, typically does not bill insurance at all and is usually considerably less expensive: a national average of $92 a month and a median of $80, consistent with a separate physician survey's average of $98.46 a month.⁵⁶

Urgent care sits outside this comparison in an important way: it is not a membership model, so there is no single annual figure to report. Simple to moderate visits typically cost $145 to $250 in cash, with complex visits running $250 to $530 or more.⁷ For a patient who visits once or twice a year, annual spending of $150 to $400 is a reasonable estimate, though that should be understood as CMT's own inference from per-visit data, not a published annual figure.

The gap in spend between GLP-1 subscriptions and concierge medicine memberships is smaller than most people in healthcare would guess. What is not smaller, at least for now, is the gap in marketing sophistication. GLP-1 telehealth companies have built acquisition systems, not just advertising campaigns.

That spending has shown up at scale on television. GLP-1 medications accounted for $360.9 million, 35.7 percent of the top ten prescription drug categories' linear TV ad spend, in the first half of 2025.⁹

That regulatory pressure is worth naming plainly and carefully, because how we name it matters. The FDA sent 30 warning letters to telehealth companies marketing compounded GLP-1 products in March 2026 alone, alleging that promotional materials blurred the line between FDA-approved medications and unapproved compounded versions.¹¹ A second coordinated wave followed in June 2026, with 25 more warning letters issued over allegedly false or misleading claims.¹² Total warning letter volume addressing compounded GLP-1 and related product claims has exceeded 55 since the FDA's enforcement push began in September 2025.¹³

To be clear about what this section is and is not saying: this is not a claim that GLP-1 medications are unsafe, that the companies who received warning letters are acting in bad faith, or that concierge medicine offers a clinical alternative to them. It is a factual account of public FDA enforcement activity, reported the same way any trade publication would report it. What it suggests is narrower and more useful: a meaningful share of the marketing built around this category has drawn regulatory attention, and patients are increasingly capable of telling the difference between a confident ad and a credible one, in any category, including ours.

The single most useful number in this research is not a price. It is an age.

A KFF Health Tracking Poll fielded in late October and early November 2025 found that current GLP-1 use is highest among adults ages 50 to 64, at 22 percent, compared with 11 percent for adults 30 to 49, 9 percent for adults 65 and older, and just 4 percent for adults 18 to 29.¹⁴ A separate, larger academic survey from the RAND Corporation, fielded through its American Life Panel with nearly 8,800 respondents, reached a similar conclusion: use peaks between ages 50 and 64 and drops by more than half after age 65, a pattern researchers linked to Medicare's lack of coverage for medications prescribed specifically for weight loss.¹⁵

Concierge medicine's own patient base skews toward the identical age range: roughly two-thirds of concierge medicine patients are age 55 and older, a pattern attributed to the higher prevalence of chronic conditions requiring continuous management in that age group.¹⁶ Direct primary care, once again, draws a different, generally younger crowd, with working-age adults 18 to 64 and their families representing the largest DPC consumer segment.¹⁷ Researchers at Drexel University's Dornsife School of Public Health found that concierge practices tend to serve a more affluent, more heavily insured population than direct primary care practices, which serve a broader range of patients.¹⁸

Urgent care use, by contrast, is nearly flat across age groups, with roughly similar shares of children, working-age adults, and older adults reporting at least one visit in the past year.¹⁹ Urgent care does not have a demographic center of gravity the way GLP-1 use and concierge medicine both do.

Put plainly: the age group most actively spending on GLP-1 medications and the age group that makes up the core of the concierge medicine patient base are the same age group. That is worth paying attention to. It is evidence that the 50-to-64-year-old patient is already comfortable paying monthly or annually, out of pocket, for a health outcome they believe in. Concierge medicine does not need to create that willingness to pay. It needs to make the case for why that spending also belongs with a physician who knows the patient's full history, not instead of any treatment a patient and their doctor decide is right for them, but alongside it.

The cost comparison above tells only part of the story. A GLP-1 subscription and a concierge medicine membership priced the same are not necessarily buying the same relationship, and the data on what happens after the prescription is filled is worth sitting with.

Real-world persistence with GLP-1 therapy is substantially lower than clinical trial completion rates. A 2025 analysis of U.S. electronic health record data covering more than 125,000 adults newly prescribed a GLP-1 found that within twelve months, 46.5 percent of patients with type 2 diabetes and 64.8 percent of patients without it had discontinued therapy, consistent with a range of other U.S. health-system datasets reporting one-year discontinuation between 37 and 81 percent depending on insurance status and measurement method.²¹ A separate study following commercially insured members without diabetes found one-year persistence of 32 percent, falling to 15 percent by two years.²² A population-based study of the first 77,310 semaglutide users in Denmark found roughly half discontinued within a year.²³

The trend is genuinely improving, which is worth stating plainly rather than burying. A 2026 analysis found one-year persistence nearly doubling, from 33.2 percent among patients who started therapy in 2021 to 60.9 percent among those who started in 2024, an improvement researchers attribute largely to the resolution of the drug supply shortages that constrained the category through early 2025.²⁴

What happens after a patient stops is also documented. A 2026 systematic review and meta-analysis published in The BMJ found that patients who discontinue GLP-1 therapy for weight management typically return to their baseline weight within roughly a year and a half.²⁵

None of this disputes that GLP-1 medications work, the clinical trial evidence for weight loss is well established, and this article isn't the place to relitigate it. It's a claim about continuity of care, which is a fair thing for a primary care publication to have a view on. A June 2026 KFF Health News investigation found that some telehealth platforms prescribing GLP-1s rely on "asynchronous" evaluations that don't include a live conversation with a clinician, and documented a case in which a patient was hospitalized after a dosing question her telehealth provider's care team initially confirmed as correct before the dose was found to be nearly nine times the typical starting amount.²⁶ A July 2026 secret-shopper study testing roughly 50 telehealth sites prescribing GLP-1s found clinical oversight inconsistent across the group.²⁷ Physicians interviewed in August 2026 pointed to specific risks that structured follow-up is meant to catch: dosing that needs reassessment as a patient loses weight, interactions with other medications, and nutritional deficiencies.²⁸ In fairness to the category, oversight varies considerably by platform; some require a live clinician visit before prescribing, and coverage of the space found more established operators actively building in scheduled check-ins and symptom tracking as the market matures.²⁹

"The chart everyone focuses on is the price. The number that actually matters is what's missing from it. Almost none of that GLP-1 spend has a physician attached to it. No one adjusting the dose, no one on side effects, no one there for what happens when a patient stops. Three thousand dollars a year buying a prescription and not much else."

Michael Tetreault, Editor-in-Chief, Concierge Medicine Today

Put simply: for a meaningful share of GLP-1 patients, three thousand dollars a year is buying a prescription and comparatively little else, no one adjusting the dose as the patient's weight and physiology change, no one managing side effects in real time, and for many, no plan for what happens if and when they stop. That's not a knock on the medication. It's a description of the care model wrapped around it, in some cases, not all, and it's the clearest data point concierge medicine has for what its own relationship-based model is actually for.

That is the strategic question this data leaves concierge medicine with. The spending is already happening. The patient is already in the market. The opportunity is not to compete with GLP-1 medications, but to be the clearer, better-earned answer for the patient already proving, with real money, that they are ready to invest in their own care.